🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

"We found that combination therapy significantly limits the #evolution of de novo resistance in E. coli, yet different #drugcombinations vary substantially in their propensity to select for #AntibioticResistance" by Leonie Jahn and Morten Sommer academic.oup.com/mbe/advance-ar…

Reduced viral loads 12 days following Pfizer-BioNTech #COVID19 vaccine. medRxiv (to appear soon). with @idanyelin Matan Levine in collaboration with #MaccabiTech; Technion Israel

Great blog post on the need for inhaled #antivirals for treatment of #COVID-19 in the community setting. fpm.org.uk/blog/inhalatio…

Using synthetic microbial communities mimicking the Brazilian sugarcane ethanol fermentation we reveal L. amylovorus as an industrial probiotic that may improve process yield. Our collaboration with Alvaro Sanchez Lab is published in Nature Communications nature.com/articles/s4146…. DTU

🎧Podcast: Intelligente tarmbakterier behandler hjernesygdomme 🦠Mikrobiolog Morten Sommer fortæller om arbejdet med at udvikle skræddersyede mikrober som ‘levende medicin’ 👉bit.ly/3eFo7SI #dkforsk #sundpol

Just out The Lancet: Largest study of reinfection, whole country of Denmark —0.65% after prior covid —Protection ~80%, lasts ≥ 7 months —Age ≥ 65 protection reduced to 47% thelancet.com/journals/lance… Steen Ethelberg University of Copenhagen Statens Serum Institut

Happy to announce that our work on broadly protective nanoparticle-based influenza vaccines has been published in Nature! rdcu.be/chpnW Supraseasonal flu vaccine = protects against seasonal flu even when that year's strain prediction is off, plus some more 1/9

Alternative proteins will transform food, mitigate climate change and drive profits. Here's how. Boston Consulting Group wef.ch/3fbPnbF

The emergence of the #SARSCoV2 variants B.1.1.7 (VOC-202012/01), 501Y.V2 (B.1.351) and P.1 (B.1.1.28.1) has aroused many concerns, including worsening #COVID19 and escape from vaccine-induced immunity.

Yesterday we announced positive data from the first part of our phase 1 trial of SYNB8802. We are developing SYNB8802 as a potential treatment for patients who have high oxalate absorption from the GI tract which causes progressive kidney damage. How did we get here? 🧵 1/9

Data from this study support testing of UNI91104, a promising candidate for viral respiratory infections such as COVID19, in patient trials. Transient irritation in the upper respiratory tract was the most frequent adverse event. Nasal application did not result in any AE.

Excited to share Phase 1 results from @UNION_Tx inhaled & intranasal niclosamide formulation. The good HV tolerability and broad antiviral effect opens exciting perspectives for the treatment of respiratory infections - including #COVID19 sciencedirect.com/science/articl… DTU

Our new paper describes a computational framework for assessing future dissemination of antibiotic resistance genes based on the gene exchange networks of their mobile elements. DTU Biosustain DTU Novo Nordisk Foundation Lundbeckfonden Nature Communications nature.com/articles/s4146…

#Niclosamide has activity against Variants of Concern of #SARS_CoV_2, including B.1.1.7 and B.1.351. biorxiv.org/content/10.110… @UNION_Tx DTU Biosustain DTU

An update on Delta, vaccination protection and viral loads from the aggregate data available, with new @PHE_uk data 1. Delta infections are characterized by very high viral loads (low Cts). When a breakthrough occurs, the load is similar to unvaccinated, but clears more rapidly

I’m really honored to be one of the recipients of this year’s Vilcek Prizes for Creative Promise. America is truly a land of opportunities. My parents immigrated to the US w/ nothing but dreams & hopes when I was young. I’m glad to be able to build a life and career here in 🇺🇸

Happy to share our collaborative work on the in vitro evaluation of Niclosamide in primary bronchial cells. #PLOSONE: Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a c ... dx.plos.org/10.1371/journa…

Characterization of new #biosensors for E coli #Nissle to aid the design of Advanced #microbiome Therapeutics pubs.acs.org/doi/full/10.10…

Microbes are already used for food production, yet, their potential for making new healthy and sustainable foods is far from exhausted. Learn more about the Microbial Foods field here: authors.elsevier.com/a/1gRm4_278y%7… Cell DTU Biosustain Novo Nordisk Foundation

Excited to share the research that lead to SNIPR BIOME development candidate for selective targeting of E. coli in the gut using #CRISPR armed #phages nature.com/articles/s4158…